Literature DB >> 8958777

Cellular receptors for sex steroids in human pituitary adenomas.

M L Jaffrain-Rea1, E Petrangeli, F Ortolani, B Fraioli, A Lise, V Esposito, L G Spagnoli, G Tamburrano, L Frati, A Gulino.   

Abstract

Cellular receptors for sex steroids (SSRs) were studied in an unselected series of 55 human pituitary tumors. Cytosolic receptors for estrogen (ERcs) and progesterone (PgRcs) were determined in all cases and cytosolic androgen receptors (ARcs) in 47 cases. Nuclear receptors (ERns, PgRns, ARns) were also studied in 33 cases. ERs and PgRs were determined by an ELISA and ARs by [3H]methyltrienolone binding. Where both cytosolic and nuclear receptors were studied (n = 33), ERs, PgRs and ARs were found in at least one subcellular fraction in 66.7, 60.6 and 81.8% of cases respectively, ERs and ARs being mainly recovered from the cytosol and PgRs from the nucleus. No linear correlation was found between pre-operative plasma steroid hormones and their specific cellular receptors. Nonetheless, the differential expression of SSRs according to sex and gonadal status at the time of surgery strongly supports their regulation by the steroid environment in vivo: PgRcs were more frequent in tumors found in women (41.4 vs 15.4%, P < 0.05), whereas a high expression of ERcs and ARcs (> 15 fmol/mg protein) was more common in tumors found in men (34.5 vs 10.3%, P < 0.05 and 54.5 vs 24.0% respectively). PgRs were positively correlated with ERns, indicating the possibility of estrogen priming of their expression, and negatively correlated with ARs in nuclear fractions. SSRs appeared to be widely distributed among pituitary tumors, although, compared with other hormone-secreting groups, prolactinomas displayed a higher ERc expression (34.8 +/- 11.3 vs 4.8 +/- 5.1 fmol/mg protein, P = 0.007) and gonadotroph cell adenomas lower ARc values (1.3 +/- 0.8 vs 38.2 +/- 10.6 fmol/mg protein, P = 0.048). Microadenomas were characterized by a higher PgR expression than macroadenomas, whereas hemorrhagic (macro)adenomas were characterized by a high ER expression (> 90%). The present results indicate that most pituitary tumors are targets for sex steroids, SSR expression being partially triggered by the steroid environment itself. Possible physiopathological and therapeutic implications of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8958777     DOI: 10.1677/joe.0.1510175

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  9 in total

Review 1.  Endocrine/paracrine control of pituitary cell proliferation and its involvement in pituitary tumorigenesis.

Authors:  M Pawlikowski
Journal:  Pituitary       Date:  1999-05       Impact factor: 4.107

2.  Functional role of estrogen in pituitary tumor pathogenesis.

Authors:  Anthony P Heaney; Manory Fernando; Shlomo Melmed
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

3.  Gliomatosis cerebri and pituitary adenoma: case report and literature review.

Authors:  A Mangiola; P De Bonis; M Guerriero; A Pompucci; C Anile
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

Review 4.  Aggressive nonfunctioning pituitary neuroendocrine tumors.

Authors:  Sérgio Portovedo; Leonardo Vieira Neto; Christina Maeda Takiya; Leandro Miranda-Alves; Paula Soares; Denise Pires de Carvalho
Journal:  Brain Tumor Pathol       Date:  2022-06-20       Impact factor: 3.154

5.  Enhanced LH action in transgenic female mice expressing hCGbeta-subunit induces pituitary prolactinomas; the role of high progesterone levels.

Authors:  Petteri Ahtiainen; Victoria Sharp; Susana B Rulli; Adolfo Rivero-Müller; Veronika Mamaeva; Matias Röyttä; Ilpo Huhtaniemi
Journal:  Endocr Relat Cancer       Date:  2010-06-03       Impact factor: 5.678

6.  Immunoexpression of androgen receptor in the nontumorous pituitary and in adenomas.

Authors:  Bernd W Scheithauer; Kalman Kovacs; Suzan Zorludemir; Ricardo V Lloyd; Seyda Erdogan; Jeffrey Slezak
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

7.  Inhibition of SKP2 Sensitizes Bromocriptine-Induced Apoptosis in Human Prolactinoma Cells.

Authors:  Jinxiang Huang; Fenglin Zhang; Lei Jiang; Guohan Hu; Wei Sun; Chenran Zhang; Xuehua Ding
Journal:  Cancer Res Treat       Date:  2016-07-28       Impact factor: 4.679

Review 8.  Hormone Replacement Therapy in Cancer Survivors - Review of the Literature.

Authors:  Tamás Deli; Mónika Orosz; Attila Jakab
Journal:  Pathol Oncol Res       Date:  2019-01-08       Impact factor: 3.201

9.  Effects of resveratrol on cell growth and prolactin synthesis in GH3 cells.

Authors:  Wang Chao; Zhang Xuexin; Su Jun; Chu Ming; Jin Hua; Guofu Li; Chunlei Tan; Wanhai Xu
Journal:  Exp Ther Med       Date:  2014-02-13       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.